case_images: PMC10640805_01
case_images: Baseline and posttreatment dermal metastases. Complete resolution of dermal metastasis after 1 dose of CHECKvacc on December 2 2021 and T-DXd from 27 December 2021 to 25 March 2022 was documented with photography.. C1D1, cycle 1 day 1 (injection day); C1D15, cycle 1 day 15.
case_images: 10.1177_17588359231210675-fig1.jpg
case_images: PMC10640805_02_10.1177_17588359231210675-fig1.jpg
case_images: fig1-17588359231210675
case_images: T-DXd on 27 December 2021 and was noted to have an excellent clinical response after initial dose with complete resolution of dermal metastasis documented in March 2022 after four doses of T-DXd (Figure 1). The complete regression was maintained until October 2022 with a total of 13 doses of T-DXd given.
case_images: CA 15-3 tumor antigen levels (U/mL) and treatment regimen.. Pembro, pembrolizumab (Keytruda, orange); SG, Sacituzumab govitecan (Trodelvy, light blue); p53MVA, p53-expressing modified vaccinia Ankara virus (black); copper chelate, (tetrathiomolybdate, green); Eribulin mesylate (Halavan, purple); CF33-hNIS-anti-PD-L1 oncolytic virus (red); T-DXd, Trastuzumab deruxtecan (T-DXd, yellow).
case_images: 10.1177_17588359231210675-fig2.jpg
case_images: PMC10640805_02_10.1177_17588359231210675-fig2.jpg
case_images: fig2-17588359231210675
case_images: A significant reduction in CA 15-3 from peak 550-64.4 U/mL was noted (Figure 2).
case_images: PMC10640805_02
case_images: Baseline and posttreatment dermal metastases. Complete resolution of dermal metastasis after 1 dose of CHECKvacc on December 2 2021 and T-DXd from 27 December 2021 to 25 March 2022 was documented with photography.. C1D1, cycle 1 day 1 (injection day); C1D15, cycle 1 day 15.
case_images: 10.1177_17588359231210675-fig1.jpg
case_images: PMC10640805_02_10.1177_17588359231210675-fig1.jpg
case_images: fig1-17588359231210675
case_images: T-DXd on 27 December 2021 and was noted to have an excellent clinical response after initial dose with complete resolution of dermal metastasis documented in March 2022 after four doses of T-DXd (Figure 1). The complete regression was maintained until October 2022 with a total of 13 doses of T-DXd given.
case_images: CA 15-3 tumor antigen levels (U/mL) and treatment regimen.. Pembro, pembrolizumab (Keytruda, orange); SG, Sacituzumab govitecan (Trodelvy, light blue); p53MVA, p53-expressing modified vaccinia Ankara virus (black); copper chelate, (tetrathiomolybdate, green); Eribulin mesylate (Halavan, purple); CF33-hNIS-anti-PD-L1 oncolytic virus (red); T-DXd, Trastuzumab deruxtecan (T-DXd, yellow).
case_images: 10.1177_17588359231210675-fig2.jpg
case_images: PMC10640805_02_10.1177_17588359231210675-fig2.jpg
case_images: fig2-17588359231210675
case_images: A significant reduction in CA 15-3 from peak 550-64.4 U/mL was noted (Figure 2).
case_images: Visualization of immune infiltrates in the tumor microenvironment (pretreatment and 1-day posttreatment). Tumor biopsies from pretreatment and 1-day posttreatment (C1D2) were stained for immune cells (CD3+, CD8+, T cells) and PD-L1+ cells using multiplex immunofluorescence. Tumor stroma (green) and cancer nests (gray) were classified using supervised machine learning (a and b). Cell phenotypes of CD4+ T cells (cyan; CD3+ CD8-), CD8+ T cells (magenta; CD3+ CD8+), and PD-L1+ cells (red; any PD-L1+ cell) were quantified using supervised machine learning (c and d). Whole slide composite images with identified cell phenotypes, pan-cytokeratin staining (gray), and DAPI staining (blue) are depicted. Scale bars are shown.. PD-L1, programmed death ligand 1.
case_images: 10.1177_17588359231210675-fig3.jpg
case_images: PMC10640805_02_10.1177_17588359231210675-fig3.jpg
case_images: fig3-17588359231210675
case_images: There was noticeable increase in T-cell population (CD4+ T cells and CD8+ T cells) cells as well as PD-L1+ cells (Figures 3 and 4) on C1D2 posttreatment biopsy. Whole slide images of segmented tissue and cell phenotypes are shown in Figure 3.
case_images: Increased immune infiltration in CF33-hNIS-anti-PD-L1-treated tumor microenvironment. Patient biopsies were assessed by multiplex IF for changes in T-cell and PD-L1+ cell densities between pretreatment (a-e) and 1-day posttreatment (C1D2; f-j). Composite images of whole tissues were stained for markers CD3 (cyan; b, g), CD8 (magenta; c, h), PD-L1 (red; d, i), pan-cytokeratin (gray), and DAPI (blue). Cell phenotypes of CD4+ T cells (CD3+ CD8-), CD8+ T cells (CD3+ CD8+), and PD-L1+ cells (any PD-L1+ cell) were quantified within the tumor stroma of tissues. The location of higher magnification images is marked by the white box. Densities of identified immune phenotypes were calculated and compared between pretreatment and C1D2 (k-m). Scale bars are shown.
case_images: 10.1177_17588359231210675-fig4.jpg
case_images: PMC10640805_02_10.1177_17588359231210675-fig4.jpg
case_images: fig4-17588359231210675
case_images: There was noticeable increase in T-cell population (CD4+ T cells and CD8+ T cells) cells as well as PD-L1+ cells (Figures 3 and 4) on C1D2 posttreatment biopsy. The pretreatment tumor microenvironment (TME) displayed a modest density of CD4+ and CD8+ T cells, with few PD-L1+ cells identified in the tumor stroma [Figure 4(a)-(e)], whereas C1D2 TME showed an increase in both CD4+ and CD8+ T cells, as well as an increase of PD-L1+ cells [Figure 4(f)-(j)].